SG11201906530TA - Inhibition of platelet aggregation using anti-human gpvi antibodies - Google Patents

Inhibition of platelet aggregation using anti-human gpvi antibodies

Info

Publication number
SG11201906530TA
SG11201906530TA SG11201906530TA SG11201906530TA SG11201906530TA SG 11201906530T A SG11201906530T A SG 11201906530TA SG 11201906530T A SG11201906530T A SG 11201906530TA SG 11201906530T A SG11201906530T A SG 11201906530TA SG 11201906530T A SG11201906530T A SG 11201906530TA
Authority
SG
Singapore
Prior art keywords
paris
international
rue
pct
rule
Prior art date
Application number
SG11201906530TA
Other languages
English (en)
Inventor
Philippe Billiald
Martine Jandrot-Perrus
Gilles Avenard
Original Assignee
Acticor Biotech
Univ Paris Diderot Paris 7
Univ Paris Xiii
Inst Nat Sante Rech Med
Univ Paris Sud 11
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acticor Biotech, Univ Paris Diderot Paris 7, Univ Paris Xiii, Inst Nat Sante Rech Med, Univ Paris Sud 11 filed Critical Acticor Biotech
Publication of SG11201906530TA publication Critical patent/SG11201906530TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201906530TA 2017-02-03 2018-02-02 Inhibition of platelet aggregation using anti-human gpvi antibodies SG11201906530TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17154658 2017-02-03
PCT/EP2018/052664 WO2018141909A1 (fr) 2017-02-03 2018-02-02 Inhibition de l'agrégation plaquettaire à l'aide d'anticorps anti-gpvi humaine

Publications (1)

Publication Number Publication Date
SG11201906530TA true SG11201906530TA (en) 2019-08-27

Family

ID=57963133

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906530TA SG11201906530TA (en) 2017-02-03 2018-02-02 Inhibition of platelet aggregation using anti-human gpvi antibodies

Country Status (13)

Country Link
US (2) US11692033B2 (fr)
EP (1) EP3577136A1 (fr)
JP (2) JP7360945B2 (fr)
KR (2) KR20240046168A (fr)
AU (2) AU2018214222C1 (fr)
BR (1) BR112019016065A8 (fr)
CA (1) CA3051169A1 (fr)
IL (1) IL268299A (fr)
MA (1) MA47415A (fr)
MX (1) MX2019009137A (fr)
SG (1) SG11201906530TA (fr)
TW (2) TWI810173B (fr)
WO (1) WO2018141909A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250026A1 (fr) * 2020-06-08 2021-12-16 Acticor Biotech Utilisation d'anticorps anti-gpvi pour le traitement du syndrome de détresse respiratoire aiguë
WO2023036815A1 (fr) * 2021-09-07 2023-03-16 Etablissement Francais Du Sang Régulation ciblée de l'activation plaquettaire et mégacaryocytaire par co-regroupement d'hétérorécepteurs
WO2023156683A1 (fr) * 2022-02-21 2023-08-24 Acticor Biotech Traitement de maladies cardiovasculaires au moyen d'anticorps anti-gpvi humaine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
FI100403B (fi) 1988-07-20 1997-11-28 Schering Ag Menetelmä glykosyloitujen tai glykosyloimattomien vampyyrilepakon sylj en plasminogeeniaktivaattoreiden valmistamiseksi
DE3903581A1 (de) 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
DK0643772T3 (da) 1992-06-03 1998-02-02 Genentech Inc Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001016321A1 (fr) * 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Adn et sequences proteiniques de glycoproteine vi (gpvi) de membranes plaquettaires et utilisations de ceux-ci
EP1224942A1 (fr) 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Utilisation de JAQ1 (anticorps monoclonal anti-GPVI) en tant que médicament actif pour la protection contre les maladies thrombotiques
CA2453986A1 (fr) 2001-07-18 2003-01-30 Merck Patent Gesellschaft Mit Beschraenkter Haftung Proteine de fusion, glycoproteine vi
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
EP1538165A1 (fr) 2003-12-03 2005-06-08 Procorde GmbH Inhibiteurs de la glycoprotéine VI construits à partir de l'anticorps monoclonal hgp 5c4
GB0511590D0 (en) 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
CN1964990B (zh) 2004-04-29 2012-12-12 大冢制药株式会社 糖蛋白ⅵ特异的抗体以及生产这些抗体的方法
WO2006118350A1 (fr) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal anti-glycoprotéine vi de membrane plaquettaire
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
EP1916259A1 (fr) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Fragment SCFV anti-gycoprotéine VI pour le traitement de la thrombose
KR20120102125A (ko) * 2009-12-18 2012-09-17 사노피 Ｇｐｖｉ에 대한 신규한 길항제 항체 및 그의 ｆａｂ 단편 및 그의 용도
CN103764680B (zh) 2011-09-01 2016-11-23 卫材R&D管理有限公司 抗人xcr1抗体
US9249406B2 (en) 2011-09-08 2016-02-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutated tissue plasminogen activators and uses thereof
BR112018002382A8 (pt) 2015-08-05 2022-12-06 Acticor Biotech Novos anticorpos anti-gvpi humano e usos dos mesmos

Also Published As

Publication number Publication date
JP2020507317A (ja) 2020-03-12
IL268299A (en) 2019-09-26
WO2018141909A1 (fr) 2018-08-09
AU2018214222C1 (en) 2021-08-05
AU2018214222A1 (en) 2019-08-01
BR112019016065A2 (pt) 2020-05-26
US20230391869A1 (en) 2023-12-07
EP3577136A1 (fr) 2019-12-11
TWI810173B (zh) 2023-08-01
JP2023109987A (ja) 2023-08-08
KR20190121767A (ko) 2019-10-28
RU2019127768A3 (fr) 2021-05-28
CA3051169A1 (fr) 2018-08-09
AU2021202612A1 (en) 2021-05-27
MA47415A (fr) 2019-12-11
CN110494447A (zh) 2019-11-22
US11692033B2 (en) 2023-07-04
KR20240046168A (ko) 2024-04-08
BR112019016065A8 (pt) 2022-10-18
KR102633644B1 (ko) 2024-02-05
TW202339799A (zh) 2023-10-16
JP7360945B2 (ja) 2023-10-13
MX2019009137A (es) 2019-12-19
US20190367608A1 (en) 2019-12-05
AU2018214222B2 (en) 2021-01-28
AU2021202612B2 (en) 2024-03-14
RU2019127768A (ru) 2021-03-03
TW201839009A (zh) 2018-11-01

Similar Documents

Publication Publication Date Title
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201910182RA (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201806261XA (en) Bcma antibodies and use of same to treat cancer and immunological disorders
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201907846VA (en) Therapeutic rna
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201809764XA (en) Humanized anti-il-1r3 antibodies
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201805941WA (en) Tgfbeta 2 antibodies
SG11201804821PA (en) A beverage capsule
SG11201810429UA (en) Anti-cd19 antibody formulations